Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786159 | 0.91 | DRD2 (0.48) | HRH3L3MBTL1TDP1CYP1A2CYP3A4 | |
| SCHEMBL31475217 | 0.84 | CXCR4 (0.47) | HRH3TDP1 | |
| SCHEMBL28002213 | 0.76 | HRH3 (0.59) | HRH3L3MBTL1TDP1CYP1A2CYP3A4 | |
| SCHEMBL30786089 | 0.76 | HRH3 (0.59) | HRH3L3MBTL1TDP1CYP1A2CYP3A4 | |
| SCHEMBL2928982 | 0.75 | MC4R (0.46) | — | |
| SCHEMBL20920751 | 0.74 | BTK (0.36) | L3MBTL1CYP3A4 | |
| SCHEMBL10815614 | 0.74 | KDM4E (0.38) | TDP1 | |
| SCHEMBL614107 | 0.72 | HRH3 (0.59) | HRH3L3MBTL1TDP1SLC6A3SIGMAR1 | |
| SCHEMBL4844013 | 0.72 | CYP1A2 (0.55) | HRH3L3MBTL1TDP1CYP1A2CYP3A4 | |
| SCHEMBL3993201 | 0.71 | HRH3 (1.00) | HRH3L3MBTL1TDP1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025082316-A1 | OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州必扬医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119604488-A | Protein tyrosine kinase inhibitor and medical application thereof | 苏州必扬医药科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024032584-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | HRH3 2004/4885L3MBTL1 607/4885TDP1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.